Ignite Creation Date:
2024-05-05 @ 10:52 PM
Last Modification Date:
2024-10-26 @ 10:25 AM
Study NCT ID:
NCT01208090
Status:
COMPLETED
Last Update Posted:
2023-01-04
First Post:
2010-09-22
Brief Title:
ACT-128800 in Patients With Moderate to Severe Chronic Plaque Psoriasis
Sponsor:
Actelion
Organization:
Actelion
Study Overview
Official Title:
Multicenter Randomized Double-blind Placebo-controlled Parallel-group Study to Evaluate the Efficacy Safety Tolerability of Two Doses of ACT-128800 an Oral S1P1 Receptor Agonist Administered up to Twenty-eight Weeks in Patients With Moderate to Severe Chronic Plaque Psoriasis
Status:
COMPLETED
Status Verified Date:
2023-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will assess the efficacy safety and tolerability of two doses of ACT 128800 in patients with moderate-to-severe chronic plaque psoriasis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None